Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lecanemab placebo-controlled phase 3 study in early Alzheimer's disease with open-label extension
2024-510887-22-00Phase 3Authorised
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of lecanemab in Alzheimer's disease (AD) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Change from baseline in Clinical Dementia Rating-Sum of Boxes and Open-label extension safety and efficacy outcomes. Planned start Sep 2019; status: authorised.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-510887-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510887-22-00.